Clinical Trials Logo

Choroidal Neovascularization clinical trials

View clinical trials related to Choroidal Neovascularization.

Filter by:

NCT ID: NCT02034006 Completed - Clinical trials for Choroidal Neovascularization Secondary to Pathologic Myopia

A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.

OLIMPIC
Start date: June 10, 2014
Phase: Phase 3
Study type: Interventional

The primary objective of the study was to investigate current criteria driving re-treatment in patients affected by Choroidal Neovascularization (CNV) secondary to Pathologic Myopia (PM) and experiencing a relapse of the disease after the first administration of ranibizumab.

NCT ID: NCT02033018 Recruiting - Clinical trials for Choroidal Retinal Neovascularization

Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization

AflibxMyopia
Start date: October 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary

NCT ID: NCT02015351 Completed - Clinical trials for Choroidal Neovascularization

Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study

Start date: September 2012
Phase: N/A
Study type: Interventional

Efficacy of monthly intravitreal anti-vascular endothelial growth factor (VEGF) associated to systemic immunosuppression in patients with Vogt-Koyanagi-Harada Disease and choroidal neovascularization. Minimum follow-up 12 months. Endpoints: 6 and 12 months of follow-up. Outcome measures: improvement of VA, decrease in central foveal thickness as measured by Optical Coherence Tomography (OCT) and absence of intra/subretinal fluid.

NCT ID: NCT01972789 Completed - Clinical trials for Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD

Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)

FLUID
Start date: October 31, 2013
Phase: Phase 4
Study type: Interventional

To evaluate and compare two individualised ranibizumab treatment regimens, differentiated by the definition of disease activity, which determines the treatment interval until the next injection. The results will be used to generate recommendations about ranibizumab treatment when using an 'inject and extend' approach to maximise patient outcomes, while reducing the need for potentially unnecessary intravitreal injections. This study will also investigate if genotypic expression influences response to intravitreal injections of ranibizumab between the two treatment arms. The study hypothesis is that intravitreal ranibizumab when administered to resolve IRF (and/or SRF >200 μm at the foveal centre) results in visual acuity benefit that is not clinically worse than intravitreal ranibizumab when administered to completely resolve both IRF and SRF in patients with wet AMD

NCT ID: NCT01968486 Completed - Clinical trials for Myopia, Degenerative

Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia

Start date: June 2012
Phase: Phase 1
Study type: Interventional

To demonstrate the efficacy of ranibizumab in combination with reduced-fluence verteporfin photodynamic therapy (RF-PDT) in patients with subfoveal choroidal neovascularization secondary to pathologic myopia (PM).

NCT ID: NCT01948830 Completed - Clinical trials for Age-related Macular Degeneration

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

TREND
Start date: December 2013
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration

NCT ID: NCT01922102 Completed - Clinical trials for Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Brilliance
Start date: September 11, 2013
Phase: Phase 3
Study type: Interventional

This study was designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia (PM)

NCT ID: NCT01908816 Completed - Clinical trials for Diabetic Retinopathy

An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.

ECLIPSE
Start date: September 26, 2013
Phase: Phase 3
Study type: Interventional

The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.

NCT ID: NCT01880788 Completed - Clinical trials for Age Related Macular Degeneration

Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD

Start date: November 2012
Phase: N/A
Study type: Observational

The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis. Group 1 - CNV secondary to CSC Group 2 - CSC without CNV Group 3 - CNV secondary to advanced AMD.

NCT ID: NCT01840410 Completed - Clinical trials for Choroidal Neovascularization (CNV)

Assess the Efficacy/Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Choroidal Neovascularization.

Start date: September 2013
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of 0.5 mg in adult patients with visual impairment due to choridal neovascularization (CNV).